[1] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies[J]. JAMA, 1998, 279(15): 1200- 1205. [2] 孙忠实,朱珠. 当代药物不良反应的特点与对策(1)[J].中国医药导刊,2003,5(1):68-70. [3] 郭晓昕,颜敏,张素敏,等. 对药品上市后安全性再评价若干问题的探讨[J]. 中国药学杂,2001,36(3): 205-208. [4] Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA[J]. N Engl J Med,2004,351(17): 1707-1709. [5] James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects[J]. N Engl J Med,2010,363(10): 905-917. [6] Bae SK, Cao S, Seo KA, et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramineN-{1-[1-(4-chlorophenyl)cyclobutyl] - 3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes[J]. Drug Metab Dispos,2008,36(8): 1679-1688. [7] Chung JY, Jang SB, Lee YJ, et al. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects[J]. J Clin Pharmacol,2011,51(1): 53-59. [8] Hsiao DJ, Wu LS, Huang SY, et al. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene[J]. Pharmacogenet Genomics,2009,19(9): 730-733. [9] 朱珠, 孙忠实. 阿洛司琼问市9个月即撤出市场[J]. 中国药学杂志,2001,36(3): 211. [10] Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology,2002,123(2): 425-432. [11] Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hyroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology,2006,130(1): 34-43. [12] Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region[J]. Science,1996,274(5292): 1527-1531. [13] Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines[J]. Clin Allergy Immunol,2002,17: 389-419. [14] Zhou Z, Vorperian VR, Gong Q, et al. Block of HERG potassinm channels by the anfihistamine astemizole and its metabolites desmethylastemizole and norastemizole[J]. Cardiovasc Electrophysiol,1999,10(6): 836-843. [15] Matsumoto S, Hirama T, Kim HJ, et al. Involvement of cyp2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole[J]. Drug Metab Dispos,2002,30(11): 1240-1245. [16] Matsumoto S, Hirama T, Kim HJ, et al. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver[J]. Xenobiotica,2003,33(6): 615-623. [17] Lee SS, Jeong HE, Liu KH,et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity[J]. Pharmacogenet Genomics,2005,15(2): 105-113. [18] Yamazaki H, Okayama A, Imai N, et al. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations[J]. Xenobiotica,2006,36(12): 1201-1209. [19] Ficker E, Obejero-Paz CA, Zhao S, et al. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene(HERG) mutations[J]. J Biol Chem, 2002,277(7):4989-4998. [20] Gussak I, Antzelevitch C, Wilde AAM,et al. Electrical Diseases of the Heart[M]. New York: Springerlink press,2008:Part V, 677-690. [21] Mück W. Clinical pharmacokinetics of cerivastatin[J]. Clin Pharmacokinet,2000,39(2): 99-116. [22] Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis[J]. N Engl J Med,2002,346(7): 539-540. [23] Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance[J]. Clin Pharmacol Ther,2006,80(6): 565-581. [24] Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes regulatory region[J]. Drug Metab Dispos,2002,30(11): 1280-1287. [25] Kameyama Y, Yamashita K, Kobayashi K,et al. Functional characterization of SLCO1B1(OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005,15(7): 513-522. [26] Ishikawa C, Ozaki H, Nakajima T, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin[J]. J Hum Genet,2004, 49(10): 582-585. [27] Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastro-oesophageal reflux in children[J]. Cochrane Database Syst Rev,2010, 4: CD002300. [28] Michalets EL, Williams CR. Drug interactions with cisapride clinical implications[J]. Clin Pharmacokinet,2000,39(1): 49-75. [29] Wang SH, Lin CY, Huang TY, et al. QT interval effects of cisapride in the clinical setting[J]. Int J Cardiol,2001,80(2/3): 179-183. [30] Cools F, Benatar A, Bougatef A, et al. The effect of cisapride on the corrected QT interval and QT dispersion in premature infants[J]. J Pediatr Gastroenterol Nutr,2001,33(2): 178-181. [31] Lowry JA, Kearns GL, Abdel-Rahman SM, et al. Cisapride: A potential model substrate toassess cytochrome P4503A4 activity in vivo[J].Clin Pharmacol Ther,2003,73(3): 209-222. [32] Yang P, Kanki H, Drolet B,et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes[J]. Circulation,2002,105(16): 1943-1948. [33] Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias[J]. J Cardiovasc Electrophysiol,2000,11(6): 691-696. [34] Finley MR, Li Y, Hua F, et al. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart[J]. Am J Physiol Heart Circ Physiol,2002,283(1): H126-138. [35] Lees-Miller JP, Duan Y, Teng GQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites[J]. Mol Pharmacol,2000,57(2): 367-374. [36] Food and Drug Administration, U.S. Department of Health and Human Services.Janssen Pharmaceutica stops marketing cisapride in the US[EB/OL]. T00-14, March 23, 2000.http: www.fda.gov bbs topics ANSWERS ANS01007.html. [37] Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation[J]. Circulation,2002,106(10): 1269- 1274. [38] Liu K, Yang T, Viswanathan PC, et al. New mechanism contributing to drug-induced arrhythmiarescue of a misprocessed LQT3 mutant[J]. Circulation,2005, 112(21): 3239-3246. [39] Elangbam CS. Current strategies in the development of anti-obesity drugs and their safety concerns[J]. Vet Pathol,2009,46(1): 10-24. [40] Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group[J]. N Engl J Med,1996,335(9): 609-616. [41] 杨景勋.芬氟拉明和右芬氟拉明的下市及其不良反应[J].药物不良反应杂志,1999,1(1): 14-17. [42] Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives[J]. Eur Respir J,2002,20(3): 518-523. [43] Morse JH. Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension[J]. Chest,2002,121(3 Suppl): S50-S53. [44] Blanpain C, Le Poul E, Parma J, et al. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine associated primary pulmonary hypertension[J]. Cardiovasc Res, 2003,60(3):518-528. [45] Gross AS, Phillips AC, Rieutord A, et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine[J]. Br J Clin Pharmacol,1996,41(4):311-317. [46] Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis[J]. Lancet,2004,364(9450): 2021-2029. [47] Department of Health and Ageing. Consumer level recall of arthritis drug[R]. Available from URL: http: //www.tga.gov.au/media/2004/040930vioxx.htm. 2004. [48] Zhang JY, Zhan J, Cook CS, et al. Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism[J]. Drug Metab Dispos,2003,31(5): 652-658. [49] Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib a specific cyclo-oxygenase-2 inhibitor[J]. Clin Pharmacokinet, 2003,42(6): 545-556. [50] St Germaine CG, Bogaty P, Boyer L, et al. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-infl ammatory drugs[J]. Am J Cardiol,2010,105(12): 1740-1745. [51] Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional rostacyclin receptor mutation potential implications for cyclooxygenase-2 inhibition[J]. Circ Res,2008,102(8): 986-993. [52] Sertindole: new drug. Another “atypical” neuroleptic; QT prolongation[J]. Prescrire Int,2007, 16(88): 59-62. [53] Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review[J]. Basic Clin Pharmacol Toxicol,2007, 100(1): 4-22. [54] Wong SL, Menacherry S, Mulford D, et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function[J]. Eur J Clin Pharmacol, 1997,52(3): 223-227. [55] Rampe D, Murawsky MK, Grau J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG[J]. J Pharmacol Exp Ther,1998,286(2): 788-793. [56] Kang J, Chen XL, Rampe D. The Antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+)channel[J]. Biochem Biophys Res Commun,2001, 286(3): 499-504. [57] Hartigan-Go K, Bateman DN, Daly AK, et al. Stereoselective cardiotoxic effects of terodiline[J]. Clin Pharmacol Ther,1996,60(1): 89-98. [58] Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system[J]. Br J Clin Pharmacol,2000,50(1): 77-80. [59] Martin RL, Su Z, Limberis JT, et al. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience[J]. J Cardiovasc Pharmacol, 2006,48(5): 199-206. [60] Thomas SH, Higham PD, Hartigan-Go K, et al. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence[J]. Br Heart J,1995,74(1):53-56. [61] Paakkari I. Cardiotoxicity of new antihistamines and cisapride[J]. Toxicol Lett,2002,127(1/2/3): 279-284. [62] Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels[J]. Proc Natl Acad Sci USA,2002,99(19): 12461-12466. [63] 杨剑,缪丽燕. 华法林的基因组学研究进展[J]. 中国临床药理学与治疗学,2006,11(12): 1326-1331. [64] Hung Si, Chung Wh, Jee Sh, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions[J]. Pharmacogenet Genomics,2006,16(4): 297-306. [65] 魏伟.对临床药理学一些基本问题研究的思考[J]. 中国临床药理学与治疗学,2008,13(10): 1081-1085. |